Drug intelligence / Profile preview

MF59-adjuvanted H5N6 cell culture-derived influenza vaccine

Development stage: Phase 2
Lead developer: CSL Seqirus
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

MF59-adjuvanted H5N6 cell culture-derived influenza vaccine (aH5N6c) is an inactivated vaccine developed for immunization against influenza A H5N6 virus. It is formulated with the MF59 adjuvant to enhance immune response. The vaccine is being studied in various priming and booster regimens, including as a heterologous booster following H5N1 vaccination. Clinical trials have evaluated its safety and immunogenicity in both adult (18-64 years) and elderly (≥65 years) populations.

Other names: Influenza A virus H5N6 vaccine

Targets

H5 HA (Influenza A hemagglutinin H5)

Beyond the preview

Go deeper on MF59-adjuvanted H5N6 cell culture-derived influenza vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MF59-adjuvanted H5N6 cell culture-derived influenza vaccine.

Explore the full profile